PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Prasterone→

Prasterone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
53-43-0
Molecular formula
C19H28O2
Molecular weight
288.4244 g/mol
Drug class
Endogenous steroid (dehydroepiandrosteroneDHEA)intracrine steroid precursor
Mechanism of action
Prasterone is an inactive endogenous steroid that is converted within tissues into active androgens and/or estrogens. The mechanism of action of vaginal prasterone for vulvovaginal atrophy and dyspareunia in postmenopausal women is not fully established.
Indications / reported uses
  • Treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, for the specific 6.5 mg vaginal insert formulation; do not extrapolate this indication to other prasterone dosage forms or routes

Sources: US DailyMed — INTRAROSA, prasterone vaginal insert (label updated 1 Jan 2026) · US FDA label — INTRAROSA · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Prasterone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Prasterone Permitted Daily Exposure (PDE) report (the Prasterone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Prasterone Occupational Exposure Limit (OEL) report (the Prasterone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.